Clinical trials: Drug-eluting Stent
Coronary Artery Disease
"JACTAX" Trial Drug Eluting Stent Trial
Prospective, multi-center, non-randomized registry. 100 patients will be enrolled at up to 10 clinical sites in Europe. The results of this study will be compared to the TAXUS™ ATLAS clinical trial to evaluate the safety of the…
- Trial name
- NCT00754728
- Testing
- JACTAX DES
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease, Coronary Artery Stenosis
Absorb IV Randomized Controlled Trial
ABSORB IV is a prospective, randomized (1:1, Absorb BVS to XIENCE), single-blind, multi-center study, registering approximately 2610 subjects from approximately 140 sites in the United States and outside the United States.
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Trial name
- NCT02173379
- Testing
- Absorb BVS, XIENCE
- Where
- 120 sites in United States, Australia and 3 more
- Volunteers
- 2,604 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
E-Five Registry: A World-Wide Registry With The Endeavor Zotarolimus Eluting Coronary Stent
The safety and efficacy of the Endeavor(TM) ABT-578 Eluting Coronary Stent System has been assessed in a series of studies. The stent is coated with a proprietary drug compound that is designed to reduce restenosis.
- Trial name
- eFive (NCT00623441)
- Testing
- Endeavor Zotarolimus Eluting Coronary Stent
- Volunteers
- 8,314 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Coronary Artery Disease
Evaluation of a XIENCE V® Endoprothesis Used for Coronary Angioplasty, for LPPR (List of Reimbursable Products and Services) Indications in Patients Monitored for 2 Years in France
The objective of this study is to prepare elements of response to the Haute Autorité de Santé (High Health Authority) of France, which is expecting data relating to the routine use of XIENCE V® endoprothesis within the 5 years…
- Trial name
- Far XIENCE V® (NCT00987506)
- Testing
- XIENCE V®
- Where
- 58 sites in France
- Volunteers
- 1,165 people
- Sponsor
- Abbott Medical Devices
Coronary Disease, Coronary Artery Disease
EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease
The purpose of this two part study is the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of the specific setting of patients with Multi-Vessel Coronary…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis
- Trial name
- EXecutive (NCT01310309)
- Testing
- Coronary artery placement of a drug-eluting stent
- Where
- 23 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Abbott Medical Devices
Coronary Disease
A Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems (GENESIS)
To demonstrate non-inferiority in 6-month angiographic in-stent late lumen loss of the pimecrolimus-eluting coronary stent (Corio) compared to the CoStar coronary stent control arm and the dual pimecrolimus/paclitaxel-eluting…
- Trial name
- NCT00322569
- Testing
- Corio™ Pimecrolimus-Eluting Coronary Stent System, SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System, Costar ™ Paclitaxel-Eluting Coronary Stent System
- Where
- United Kingdom
- Volunteers
- 246 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
Optical Frequency Domain Imaging (OFDI) Assessed Strut Coverage of New Terumo DES
Purpose of this study is to evaluate, after implantation of a drug eluting stent (DES), coverage of the stent struts by new tissue.
- Trial name
- DISCOVERY123 (NCT01844843)
- Testing
- TCD-10023 drug eluting stent
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 60 people
- Sponsor
- Terumo Europe N.V.
Coronary Artery Disease
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM SV (NCT01498692)
- Testing
- PROMUS Element Coronary Stent System
- Where
- 23 sites in United States, Australia and 4 more
- Volunteers
- 94 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
The Optical Coherence Tomography Drug Eluting Stent Investigation
The objective of this study is to evaluate the completeness of struts coverage and vessel wall response to the new generation JACTAX drug-eluting stent vs Taxus stent in de novo coronary artery lesions at 6 months post index…
- Trial name
- OCTDESI (NCT00776204)
- Testing
- JACTAX Drug eluting stent, JACTAX LD drug eluting stent, Taxus Libertè
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease, Atherosclerosis
MASCOT - Post Marketing Registry
To collect post marketing surveillance data on patients receiving at least one Combo Bio-Engineered Sirolimus Eluting Stent when used according to the Instructions for Use.
- Trial name
- MASCOT (NCT02183454)
- Testing
- OrbusNeich COMBO stent
- Where
- Netherlands
- Volunteers
- 2,500 people
- Sponsor
- OrbusNeich
Peripheral Arterial Disease, Superficial Femoral Artery Stenosis
Study of Drug Eluting Peripheral Vascular Stent System in Superficial Femoral Artery Stenosis and /or Occlusion
Evaluation of drug eluting peripheral vascular stent system for the treatment of superficial femoral artery stenosis and / or occlusion, there is better in effectiveness and clinical performance compared with similar products…
- Conditions
- Peripheral Arterial Disease, Superficial Femoral Artery Stenosis, Superficial Femoral Artery Occlusion
- Trial name
- NCT03121430
- Testing
- Drug eluting peripheral vascular stent system, Nitinol Stent System
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Zhejiang Zylox Medical Device Co., Ltd.
Atherosclerosis, Coronary Artery Disease
XIENCE V® EXCEED: Evaluation of XIENCE V® Catheterization Lab Endpoints and Excellence in Delivery
This trial is to assess physician-determined XIENCE V® EECSS acute performance, deliverability and resource utilization in the catheterization lab during commercial use by various physicians with a range of coronary stenting…
- Trial name
- EXCEED (NCT00731237)
- Where
- 44 sites in United States
- Volunteers
- 2,517 people
- Sponsor
- Abbott Medical Devices
Heart Diseases
Galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System First-in-man Study
The Galaxy First-in-man study is a small pilot. single arm research , which will enroll a total of 45 patients. The goal is to access the feasibility, safety and efficacy of Rapamycin Drug-Eluting Bioresorbable Coronary Stent…
- Trial name
- NCT02844270
- Testing
- Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
- Volunteers
- 45 people
- Sponsor
- Shanghai Bio-heart Biological Technology Co., Ltd.
Coronary Artery Disease
A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)
PIONEER-II RCT trial is a prospective, multicenter, randomized, non-inferiority registry trial. 539 subjects from about 40 interventional cardiology centers in China will be enrolled to evaluate In-stent late lumen loss(LLL) as…
- Trial name
- RCT (NCT02698839)
- Testing
- BuMA Supreme, BuMA™
- Where
- China
- Volunteers
- 539 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Peripheral Arterial Disease
Zilver PTX Drug-Eluting Peripheral Stent Study
This randomized, post-market clinical study is intended to evaluate the delivery and deployment of longer Zilver PTX stents (≥ 100 mm) compared to shorter Zilver PTX stents (≤80 mm) for treatment of lesions of the above-the-knee…
- Trial name
- NCT01348425
- Testing
- Longer Zilver PTX Stents, Shorter Zilver PTX Stents
- Where
- 4 sites in Germany, Switzerland
- Volunteers
- 45 people
- Sponsor
- Cook Group Incorporated
Coronary Artery Disease
First-In-Human Trial of the MiStent Drug-Eluting Stent (DES) in Coronary Artery Disease
The DESSOLVE I clinical trial is to assess the safety and performance of the sirolimus-eluting MiStent SES.
- Trial name
- DESSOLVE-I (NCT01247428)
- Testing
- MiStent SES
- Where
- 5 sites in Australia, Belgium and 1 more
- Volunteers
- 30 people
- Sponsor
- Micell Technologies
Coronary Artery Stenosis
Cordimax China Post Market Surveillance
Study purpose: This study is a prospective, randomized, controlled multicenter clinical research, which is to assess the effect of Cordimax and Xience V drug-eluting stents as they dealing with all kinds of complex lesions in the…
- Trial name
- NCT03185221
- Testing
- Cordimax, XIENCE V
- Where
- China
- Volunteers
- 3,660 people
- Sponsor
- Shandong Branden Med.Device Co.,Ltd
Acute ST Segment Elevation Myocardial Infarction
Safety and Efficacy of TCD-10023 (Ultimaster) Drug-eluting Stent in STEMI Patients - MASTER Study
The aim of the study is to demonstrate the safety and efficacy of the TCD-10023 (Ultimaster) sirolimus eluting stent in patients with acute ST-elevation myocardial infarction (STEMI), by proving superiority with respect to…
- Trial name
- MASTER (NCT02828683)
- Testing
- PCI in patients with ST-elevation myocardial infarction
- Where
- 13 sites in Brazil, Italy and 3 more
- Volunteers
- 500 people
- Sponsor
- Terumo Europe N.V.
Coronary Artery Disease, Coronary Artery Stenosis
To Evaluate the Performance and Safety of RisoR Crest Everolimus Eluting Coronary Stent System
The study will evaluate the performance and safety of RisoR Crest Everolimus Eluting Coronary Stent System. A total of 2000 participants will be included in the study from India and Italy.
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Percutaneous Coronary Intervention, de Novo Lesions in Native Coronary Arteries
- Trial name
- PACIFIER (NCT07098195)
- Testing
- Coronary Stent
- Volunteers
- 2,000 people
- Sponsor
- Poly Medicure Limited
Coronary Arterial Disease (CAD)
Clinical Investigation for Everolimus Drug Eluting Stent
History of Device Development and Study Rationale: Drug-eluting stents (DES) revolutionized percutaneous coronary intervention (PCI) by significantly reducing restenosis and the need for repeat procedures compared to bare-metal…
- Trial name
- EverGreen (NCT06769217)
- Testing
- Drug Eluting Coronary Stent
- Where
- 5 sites in India, Indonesia
- Volunteers
- 888 people
- Sponsor
- Frisch Medical Device Private Limited